Hydroxy aliphatic substituted phenyl aminoalkyl ether compounds of formula (I), and compositions thereof, are useful as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or mental disorders associated with cognitive deficits.

##STR00001##

New hydroxy aliphatic substituted phenyl aminoalkyi ether compounds of formula (I), compositions thereof and their use as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or mental disorders associated with cognitive deficits. ##STR00001##

New hydroxy aliphatic substituted phenyl aminoalkyi ether compounds of formula (I), compositions thereof and their use as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or mental disorders associated with cognitive deficits. ##STR00001##

A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.

Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ER) modulator/degrader (SERM/SERD), having utility for the treatment of ER+ cancers including breast cancer are described.

Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ER) modulator/degrader (SERM/SERD), having utility for the treatment of ER+ cancers including breast cancer are described.

Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ER) modulator/degrader (SERM/SERD), having utility for the treatment of ER+ cancers including breast cancer are described.

Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ER) modulator/degrader (SERM/SERD), having utility for the treatment of ER+ cancers including breast cancer are described.

Disclosed are systems and methods for desalinating high-salinity brines via temperature swing solvent extraction (TSSE) using an amine-based solvent.

Disclosed are systems and methods for desalinating high-salinity brines via temperature swing solvent extraction (TSSE) using an amine-based solvent.